Yescarta Sales Impacted by COVID-19; ZUMA-7 Data Delayed to H1 2021; Q3 2020 Gilead Earnings Call Summary

On Wednesday, October 28, Gilead held their Q3 2020 earnings call (press release / presentation). Management highlighted the recent launch of Tecartus and the reduction in Yescarta sales. Of note, Gilead confirmed that ZUMA-7’s data readout has been delayed to H1 2021. Furthermore, updated Yescarta data is anticipated for ASH 2020. Below, Celltelligence provides thoughts on Gilead’s launch strategy for Tecartus and implications for Yescarta sales in an ongoing COVID-19 environment.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.